Ipamorelin + Sermorelin Combo
Growth Hormone Secretagogue CombinationresearchAlso known as: Ipamorelin/Sermorelin, Sermorelin/Ipamorelin Stack, GH Secretagogue Combo
A popular clinical combination of two growth hormone secretagogues that work through complementary pathways — GHRH receptor (sermorelin) and ghrelin receptor (ipamorelin) — for synergistic GH release with minimal side effects.
Overview
The ipamorelin + sermorelin combination is one of the most widely prescribed peptide protocols in anti-aging and hormone optimization clinics. Sermorelin is a GHRH analog (growth hormone-releasing hormone) that stimulates GH release through the GHRH receptor, while ipamorelin is a selective growth hormone secretagogue that stimulates GH release through the ghrelin (GHS-R1a) receptor. When combined, they produce synergistic GH release that exceeds either peptide alone, mimicking the natural physiological pulsatile pattern of GH secretion. This combination is preferred over direct HGH therapy because it maintains the body's natural feedback mechanisms, produces physiological GH pulses rather than supraphysiological sustained levels, and has a superior safety profile. It is commonly used for anti-aging, improved body composition, sleep quality, recovery, and overall vitality.
Mechanism of Action
The combination exploits two complementary GH release pathways: (1) Sermorelin binds GHRH receptors on pituitary somatotrophs, initiating GH gene transcription and release via cAMP/PKA signaling; (2) Ipamorelin binds ghrelin receptors (GHS-R1a) on somatotrophs, amplifying GH release through IP3/DAG/PKC signaling; (3) The dual-pathway stimulation creates synergistic GH pulses greater than either alone; (4) Both maintain negative feedback — GH release is still modulated by somatostatin and IGF-1; (5) Ipamorelin is highly selective for GH release without affecting cortisol, prolactin, or ACTH; (6) The combined effect improves deep sleep GH pulses, enhancing overnight recovery.
Molecular Formula
Sermorelin: C149H246N44O42S; Ipamorelin: C38H49N9O5
Molecular Weight
Sermorelin: 3357.93 g/mol; Ipamorelin: 711.85 g/mol
Sequence
Sermorelin: GHRH(1-29)NH2; Ipamorelin: Aib-His-D-2Nal-D-Phe-Lys-NH2
Dosage Protocols
Dose Range
100mcg each – 300mcg each
Frequency
Once daily (evening)
Route
subcutaneous
Cycle Length
3-6 months
Inject both peptides together subcutaneously before bed on an empty stomach (2+ hours fasted). The evening dose maximizes the synergy with natural sleep-related GH pulse. Typical protocol: 200mcg ipamorelin + 200mcg sermorelin.
Source: Anti-aging clinic protocols
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
Combination vial
Last Updated
2026-02
Popular anti-aging GH combo. Telehealth clinics: $200-400/mo. Compounding pharmacies offer pre-mixed vials.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Injection site redness | mild |
| Head rush / Flushing | mild |
| Increased hunger | mild |
| Water retention | mild |
| Vivid dreams | mild |
Pros & Cons
Synergistic GH release greater than either peptide alone through dual-pathway activation
Maintains natural GH pulsatility and feedback mechanisms unlike exogenous HGH
Excellent safety profile — ipamorelin is the most selective GH secretagogue with no cortisol/prolactin effects
Dramatic improvement in sleep quality and overnight recovery reported by users
Available through compounding pharmacies with prescription in the US
Requires daily subcutaneous injections, often before bedtime on empty stomach
Limited formal clinical trial data for the specific combination
Benefits diminish if dosing timing (fasting, bedtime) is not followed consistently
Cost of compounded peptides can be significant ($200-500/month)
Research Studies
🩸 Blood Work
IGF-1
Combined GHRH+GHRP produces significant GH elevation
Fasting Blood Glucose
Monitor glucose with GH elevation
Fasting Insulin
Monitor insulin resistance
Thyroid Panel (TSH, T3, T4)
GH affects thyroid conversion
Synergistic GHRH + GHRP combination. Monitor IGF-1 closely as combined effect may be stronger than expected.
Legal Status
Sermorelin was previously FDA-approved (Geref) but discontinued commercially. Both peptides are available through compounding pharmacies with a prescription in the US. Ipamorelin is research-only in most jurisdictions. The combination is commonly prescribed by anti-aging clinics.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.